Company Performance - Pacific Biosciences of California (PACB) ended the recent trading session at $1.52, showing a +2.01% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.37% [1] - Prior to today's trading, shares of Pacific Biosciences had gained 17.32%, significantly exceeding the Medical sector's gain of 5.9% and the S&P 500's gain of 4.26% [1] Earnings Forecast - The upcoming earnings disclosure is anticipated to show an EPS of -$0.16, reflecting a 5.88% growth compared to the same quarter last year [2] - Revenue is forecasted to be $40.38 million, indicating a 1.03% growth compared to the corresponding quarter of the previous year [2] Full Year Estimates - For the full year, analysts expect earnings of -$0.6 per share and revenue of $158.75 million, representing changes of +27.71% and +3.07% respectively from last year [3] Analyst Sentiment - Recent adjustments to analyst estimates for Pacific Biosciences are indicative of shifting short-term business dynamics, with upward revisions reflecting analysts' positive outlook on the company's operations and profit generation capabilities [4] - The Zacks Rank system, which assesses these estimate changes, currently ranks Pacific Biosciences as 3 (Hold) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, holds a Zacks Industry Rank of 144, placing it in the bottom 42% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Pacific Biosciences of California (PACB) closed the most recent trading day at $1.29, moving +1.57% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.44% for the day. Meanwhile, the Dow experienced a rise of 0.14%, and the technology-dominated Nasdaq saw an increase of 0.7%. The stock of maker of genetic analysis technology has fallen by 7.97% in the past month, lagging the Medical sector's gain of 1.25% and the S&P 500's gain of 4.03%.Analysts and investors ali ...

Group 1 - Pacific Biosciences of California (PACB) closed at $1.17, reflecting a -7.14% change from the previous day, underperforming the S&P 500's daily loss of 0.05% [1] - The stock has increased by 2.44% over the past month, which is below the Medical sector's gain of 7.77% and the S&P 500's gain of 3.44% [1] Group 2 - The company is expected to report an EPS of -$0.16, which is a 5.88% increase from the prior-year quarter, with a revenue estimate of $40.31 million, up 0.85% from the prior-year quarter [2] - For the annual period, the Zacks Consensus Estimates predict an EPS of -$0.6 and revenue of $159.08 million, indicating increases of +27.71% and +3.29% respectively from the last year [3] Group 3 - Recent changes in analyst estimates for Pacific Biosciences are important as they reflect short-term business trends, with positive revisions indicating analysts' confidence in the company's performance [4] - Adjustments in estimates are linked to stock price performance, and the Zacks Rank system is designed to leverage this relationship [5] Group 4 - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 rated stocks averaging an annual return of +25% since 1988; currently, Pacific Biosciences holds a Zacks Rank of 3 (Hold) [6] Group 5 - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 94, placing it in the top 39% of over 250 industries, indicating strong performance potential [7]

Company Performance - Pacific Biosciences of California (PACB) closed at $1.54, reflecting a -6.1% change from the previous day, underperforming the S&P 500's daily loss of 0.3% [1] - Over the past month, PACB shares have increased by 32.26%, significantly outperforming the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64% [1] Upcoming Earnings - The company's earnings report is scheduled for August 7, 2025, with projected EPS of -$0.18, indicating a 10.00% increase compared to the same quarter last year [2] - Revenue is estimated to be $36.46 million, reflecting a 1.26% increase from the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, Zacks Consensus Estimates predict earnings of -$0.64 per share and revenue of $155.44 million, representing changes of +22.89% and +0.92% respectively from the previous year [3] Analyst Estimates - Recent modifications to analyst estimates for Pacific Biosciences indicate evolving short-term business trends, with upward revisions suggesting analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently assigns PACB a rank of 2 (Buy) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 158, placing it in the bottom 37% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Viewpoint - Pacific Biosciences of California (PACB) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is based on changes in earnings estimates, tracking EPS estimates from sell-side analysts through a consensus measure known as the Zacks Consensus Estimate [2]. - The Zacks rating upgrade reflects an improvement in the earnings outlook for Pacific Biosciences, which could positively impact its stock price [4][6]. - Rising earnings estimates correlate strongly with stock price movements, as institutional investors adjust their valuations based on these estimates [5][6]. Performance of Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of Pacific Biosciences to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2025, Pacific Biosciences is expected to earn -$0.64 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 10.2% over the past three months [9].

Group 1 - Pacific Biosciences of California (PACB) ended the recent trading session at $1.18, with a +1.72% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.38% [1] - The company has seen a 5.45% increase in its share price over the past month, while the Medical sector gained 4.64% and the S&P 500 gained 6.6% during the same period [1] Group 2 - The upcoming financial results for Pacific Biosciences are anticipated to show an EPS of -$0.18, reflecting a 10% growth compared to the same quarter last year, with a revenue forecast of $36.46 million, indicating a 1.26% growth year-over-year [2] - For the annual period, the Zacks Consensus Estimates predict earnings of -$0.64 per share and revenue of $155.12 million, representing shifts of +22.89% and +0.72% respectively from the previous year [3] Group 3 - Recent modifications to analyst estimates for Pacific Biosciences indicate shifting dynamics in short-term business patterns, with upward revisions reflecting analysts' positive outlook on the company's operations and profit generation capabilities [4] - The Zacks Rank system, which assesses estimate changes, currently places Pacific Biosciences at a Zacks Rank of 3 (Hold), with an 8.36% increase in the consensus EPS estimate over the last 30 days [6] Group 4 - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 143, placing it within the bottom 42% of over 250 industries, indicating relative underperformance compared to higher-ranked industries [7]

Core Viewpoint - Pacific Biosciences of California (PACB) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The recent upgrade indicates a positive outlook for Pacific Biosciences' earnings, suggesting potential buying pressure and an increase in stock price [3][5]. - The Zacks Consensus Estimate for Pacific Biosciences has increased by 5.1% over the past three months, with expected earnings of -$0.67 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 19.3% [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places Pacific Biosciences in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].